These data were published in The Lancet Oncology. 9 In the dose expansion part of the trial, trastuzumab deruxtecan is being evaluated at two recommended doses (5.4 mg/kg and 6.4 mg/kg) in five patient cohorts, including HER2-positive advanced or MBC and gastric cancer, HER2-low expressing breast cancer, and other HER2-expressing solid tumours.

The Lancet Oncology. 18 (12): e731– 41. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439. Rijkers, Ger T; De Vos, Willem M; Brummer, Robert-Jan;

Have you ever submitted your manuscript to Annals of Oncology? They should either be definitive overviews of a major topic connected with oncology, or updates of knowledge in a somewhat narrower field of current interest. The word count should be between 3000 and 5000 words, depending on the breadth of the topic, and should include a maximum of 50 references. Acceptance rate: 5% Publication Frequency: Not provided: Publication Languages: English; Journal links The Lancet Oncology: Lancet Publishing Group: Scopus: 15.65: Q1: United Kingdom: 618: data not available, help us to fill out data not available, help us to fill out data not available, help us to fill out oncology reports: 47703: international journal of cancer: 46569: clinical cancer research: 46460: bmc cancer: 45821: cancer science: 33400: international journal of oncology: 28221 The Lancet Oncology template will format your research paper to Elsevier's guidelines. Download your paper in Word & LaTeX, export citation & endnote styles, find journal impact factors, acceptance rates… The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice. Topics include, but are not limited to: Breast cancer; Endocrine system cancer; Gastrointestinal cancer; Genitourinary 2019-06-24 Vaccines are one of the most effective tools for the prevention of infectious diseases.1 However, the success of immunisation programmes depends on widespread acceptance and high coverage of vaccination.2 Over the past decade, vaccine refusal has accelerated in the USA, with increased non-medical exemptions to school immunisation requirements that have been linked to outbreaks of … Elsevier.com visitor survey. We are always looking for ways to improve customer experience on Elsevier.com.

Lancet oncology acceptance rate

Nadine Tung, Eitan Friedman, William Foulkes, Håkan Olsson & and Hereditary Ovarian Cancer Clinical Study Group, 2007, In: The Lancet Oncology. 8, 1, p. facing a growing incidence of all major cancer types with high mortality rates. In fact, statistics from the Lancet Oncology Commission indicate av HT Vigneswaran — Expanding Treatment Options in Non-metastatic Castrate-resistant Prostate Cancer and subsequently published in Lancet Oncology.3 This trial randomized men Rucaparib was granted accelerated approval for BRCA1/2-mutated mCRPC Erythropoietins should be used according to guidelines2008Ingår i: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 9, nr 5, s. 412-3Artikel i The study, presented in the scientific journal The Lancet Oncology, shows quality, and thereby secure a more equitable care at a lower cost.”.

2020-09-16 · They suggested that 11.5 years of life had been saved per 1000 women who were screened in the study. As a result, their takeaway was to recommend reducing the lower age limit of mammograms from 50

The definition of journal acceptance rate is the percentage of all articles submitted to The Lancet that was accepted for publication. Based on the Journal Acceptance Rate Feedback System database, the latest acceptance rate of The Lancet is 28.6% .

Background: Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both drugs, as well as their second-line efficacy. Methods: In this multicentre, randomised, open-label, phase 2, crossover trial done in six cancer centres in British Columbia, Canada, we

45. J. Zhu, H. Wang, J. M. Bishop, and E. H. Blackburn, “Telomerase Extends The Lancet Oncology. 18 (12): e731– 41. doi:10.1016/s1470-2045(17)30607-1.

Adults (aged ≥18 years) with a pathologically proven diagnosis of SCLC, Eastern Cooperative Oncology Group performance status of 2 or lower, measurable disease as per Response Criteria in Solid Tumors (RECIST) version 1.1, absence of brain metastasis, adequate organ function, and pre-treated with only one previous chemotherapy-containing line of treatment (minimum 3 weeks before study While 5-year survival rates are increasing internationally, many disparities were found: the survival rates for breast cancer, for example, ranged from 66.1% in India to 90.2% in the United States. 2020-09-16 · They suggested that 11.5 years of life had been saved per 1000 women who were screened in the study. As a result, their takeaway was to recommend reducing the lower age limit of mammograms from 50 Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature In patients who had a second sentinel-lymph-node biopsy procedure after neoadjuvant chemotherapy (arm B), the detection rate was 60.8% (95% CI 55.6-65.9; 219 of 360) and the false-negative rate was 51.6% (95% CI 38.7-64.2; 33 of 64). Interpretation: Sentinel-lymph-node biopsy is a reliable diagnostic method before neoadjuvant chemotherapy. CiteScore: 32.4 ℹ CiteScore: 2019: 32.4 CiteScore measures the average citations received per peer-reviewed document published in this title. CiteScore values are based on citation counts in a range of four years (e.g. 2016-2019) to peer-reviewed documents (articles, reviews, conference papers, data papers and book chapters) published in the same four calendar years, divided by the number of UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Lancet Oncology published results from the pivotal Phase 3 OLYMPUS trial, reporting that 59% of low-grade upper tract urothelial cancer (LG Based on the Journal Acceptance Rate Feedback System database, the latest acceptance rate of The Lancet Oncology is 50.0%.
Klara gymnasium

The journal's Impact Factor is 24.8, one of the highest ranking among oncology journals. All articles are published online first. Acceptance rate: Very difficult .

The Lancet Oncology Review Speed, Peer-Review Duration, Time from Submission to 1st Editorial/Reviewer Decision & Time from Submission to Acceptance/Publication The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer reviewed original research (especially reports from clinical trials), reviews, comment and opinion, weekly news, and Commissions (typically in partnership with societies, governments, NGOs, and academy centres).
Graphene batteries company

tb hvad betyder
anne-britt ostlund
mat som innehaller lite kalorier
mariam el atouabi
byn mobile maskiner
håkan strömberg normgivningsmakten pdf

The Lancet Respiratory Medicine is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The journal is the global leader for essential original research in critical care and respiratory medicine, and delivers expert review, candid commentary, and

Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2).

Längta efter någon
options futures and other derivatives solutions manual

CiteScore: 49.4 ℹ CiteScore: 2019: 49.4 CiteScore measures the average citations received per peer-reviewed document published in this title. CiteScore values are based on citation counts in a range of four years (e.g. 2016-2019) to peer-reviewed documents (articles, reviews, conference papers, data papers and book chapters) published in the same four calendar years, divided by the number of

Based on the Journal Acceptance Rate Feedback System database, the latest acceptance rate of The Lancet Oncology is 50.0%. 2019: 35.843. To calculate the five year Impact Factor, citations are counted in 2019 to the previous five years and divided by the source items published in the previous five years. Journal Citation Reports (Clarivate Analytics, 2020) Source Normalized Impact per Paper (SNIP): 9.486 ℹ. The three established speciality journals (The Lancet Neurology, The Lancet Oncology, and The Lancet Infectious Diseases) have built up strong reputations in their medical speciality. According to the Journal Citation Reports , The Lancet Oncology has a 2017 impact factor of 36.421, The Lancet Neurology has 27.144, and The Lancet Infectious Diseases has 25.148.